FDC Ltd

FDC Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.323.2 on 24 March 2026, marking a significant decline in its stock price amid a sustained downward trend over recent sessions.

FDC Ltd’s share price declined to a fresh 52-week low of Rs.325.9 on 23 March 2026, marking a significant downturn for the pharmaceutical company amid subdued financial results and broader market weakness. The stock’s recent performance reflects ongoing challenges in growth and profitability, compounded by a cautious market environment.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change comes amid a backdrop of subdued stock performance and challenging sector dynamics, prompting a reassessment of its price attractiveness relative to peers and historical benchmarks.

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 18 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

FDC Ltd, a player in the Pharmaceuticals & Biotechnology sector, has declined to a fresh 52-week low, closing near Rs 330.05, marking a significant point in its recent price trajectory. The stock’s performance reflects ongoing pressures, with a notable underperformance relative to its sector and broader market indices.

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 07 March 2026, providing investors with the latest insights into its performance and outlook.

FDC Ltd’s share price declined sharply to a fresh 52-week low of Rs.330.05 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s shares have been under pressure for several sessions, reflecting a combination of subdued financial performance and valuation concerns.

FDC Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a new 52-week low of Rs.355.05 today, marking a significant decline amid a sustained downward trend. The stock has underperformed both its sector and the broader market, reflecting ongoing concerns about its financial performance and valuation metrics.

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

FDC Ltd’s valuation metrics have recently shifted from fair to expensive territory, prompting a reassessment of its price attractiveness relative to historical levels and peer benchmarks within the Pharmaceuticals & Biotechnology sector. Despite a strong market cap grade, the company’s deteriorating mojo score and downgraded rating to Strong Sell highlight growing investor caution amid subdued returns and stretched multiples.

Shares of FDC Ltd, a player in the Pharmaceuticals & Biotechnology sector, declined sharply to hit a new 52-week low of Rs.357.45 on 6 February 2026, marking a significant milestone in the stock’s ongoing downward trajectory.

FDC Ltd., the Mumbai-based pharmaceutical company specialising in formulations and active pharmaceutical ingredients, delivered a disappointing Q3 FY26 performance, with net profit declining 23.60% year-on-year to ₹28.30 crores despite relatively flat revenue growth. The stock has plunged 28.90% from its 52-week high of ₹528.30, currently trading at ₹375.60 with a market capitalisation of ₹6,202 crores, reflecting mounting investor concerns over deteriorating operational efficiency and margin compression.

FDC Ltd’s valuation metrics have shifted notably, with its price-to-earnings (P/E) and price-to-book value (P/BV) ratios moving into the expensive territory compared to historical averages and peer benchmarks. This re-rating, coupled with a recent downgrade to a Strong Sell rating by MarketsMOJO, underscores growing concerns about the stock’s price attractiveness within the Pharmaceuticals & Biotechnology sector.

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 01 February 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 January 2026, providing investors with the latest insights into the company’s performance and outlook.